E2F1 and neoplasm: SNORA38B plays a role in promoting tumor progression in NSCLC by directly binding to E2F transcription factor (E2F1) and regulating the GAB2/AKT/mTOR pathway thereby contributing to the development of an immunosuppressive tumor microenvironment.